Astec LifeSciences Grants 1,142 Stock Options Under ESOP 2012 to Eligible Employee

1 min read     Updated on 01 May 2026, 04:14 AM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Astec LifeSciences Limited's Nomination and Remuneration Committee approved the grant of 1,142 stock options under ESOP 2012 to an eligible employee at an exercise price of Rs.10/- per option. The options carry a 3-year vesting period with 1-month exercise window and comply with SEBI regulations.

powered bylight_fuzz_icon
39128068

*this image is generated using AI for illustrative purposes only.

Astec LifeSciences Limited has announced the grant of 1,142 stock options to an eligible employee under its Employee Stock Option Plan 2012 (ESOP 2012). The grant was approved by the company's Nomination and Remuneration Committee on April 30, 2026, in compliance with regulatory requirements.

Stock Option Grant Details

The company has provided comprehensive details regarding the stock option grant structure and terms:

Parameter: Details
Number of Options: 1,142 stock options
Exercise Price: Rs.10/- per option
Face Value per Share: Rs.10/-
Vesting Period: 3 years
Exercise Window: 1 month from vesting date

Each stock option entitles the holder to apply for one equity share of the company with a face value of Rs.10/-. The exercise price has been set at Rs.10/- per option, matching the face value of the underlying shares.

Regulatory Compliance and Framework

The stock option grant has been structured in accordance with multiple regulatory frameworks to ensure full compliance. The grant falls under the provisions of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. Additionally, the announcement has been made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Vesting and Exercise Terms

The granted options follow a structured vesting schedule designed to align employee interests with long-term company performance. The options will vest over a period of 3 years, providing a gradual release of benefits to the eligible employee. Once vested, the options must be exercised within 1 month from the date of vesting, though the Nomination and Remuneration Committee retains the authority to determine alternative exercise periods if deemed appropriate.

Corporate Communication and Documentation

Astec LifeSciences has ensured transparent communication of this development through multiple channels. The company has formally notified both BSE Limited and National Stock Exchange of India Limited about the stock option grant through official regulatory filing. The communication was signed by Tejashree Pradhan, Company Secretary & Compliance Officer, and the information has also been uploaded on the company's official website at www.godrejastec.com , ensuring accessibility for all stakeholders and maintaining compliance with disclosure requirements.

Historical Stock Returns for Astec Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
-0.81%-6.20%+19.82%+3.45%+1.00%-39.94%

Will Astec LifeSciences expand its ESOP program to include more employees as part of a broader talent retention strategy?

How might this stock option grant signal the company's expectations for share price performance over the next three years?

Could this ESOP grant indicate upcoming organizational changes or key project assignments requiring enhanced employee commitment?

Astec LifeSciences Reports Financial Results for Quarter and Year Ended March 31, 2026

2 min read     Updated on 29 Apr 2026, 12:55 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Astec LifeSciences Limited published audited financial results for Q4 and FY26, showing total income of ₹45,321.65 lakhs for the year against ₹38,693.22 lakhs in FY25. Despite revenue growth, the company reported a comprehensive loss of ₹8,041.45 lakhs, though this was an improvement from the ₹13,453.79 lakhs loss in the previous year. The company's net worth increased significantly to ₹39,091.84 lakhs from ₹23,501.65 lakhs, while debt equity ratio improved to 1.15 from 2.36.

powered bylight_fuzz_icon
38949941

*this image is generated using AI for illustrative purposes only.

Astec LifeSciences Limited has published its audited financial results for the quarter and financial year ended March 31, 2026, following approval by the Board of Directors on April 27, 2026. The results were disclosed through newspaper publications on April 28, 2026, in Business Standard (English) and Mumbai Lakshdeep (Marathi), as required under SEBI regulations.

Financial Performance Overview

The company's financial performance for FY26 showed mixed results with increased revenue but continued losses. Total income from operations reached ₹45,321.65 lakhs for the full year, representing growth from ₹38,693.22 lakhs in the previous financial year.

Metric FY26 (Audited) FY25 (Audited) Q4 FY26 Q3 FY26 Q4 FY25
Total Income from Operations (₹ lakhs) 45,321.65 38,693.22 16,125.62 12,553.55 12,031.82
Net Loss Before Tax (₹ lakhs) (7,890.58) (14,098.92) (790.01) (1,358.08) (1,566.10)
Net Loss After Tax (₹ lakhs) (8,087.62) (13,471.17) (774.70) (1,568.53) (1,607.90)
Total Comprehensive Loss (₹ lakhs) (8,041.45) (13,453.79) (753.67) (1,554.73) (1,631.94)

Capital Structure and Financial Position

The company's capital structure showed significant changes during the year, with equity share capital increasing to ₹2,228.22 lakhs from ₹1,961.14 lakhs in the previous year. Net worth improved substantially to ₹39,091.84 lakhs compared to ₹23,501.65 lakhs in FY25.

Parameter FY26 FY25 Change
Equity Share Capital (₹ lakhs) 2,228.22 1,961.14 +267.08
Securities Premium Account (₹ lakhs) 29,502.82 6,139.18 +23,363.64
Net Worth (₹ lakhs) 39,091.84 23,501.65 +15,590.19
Outstanding Debt (₹ lakhs) 44,892.99 55,454.41 -10,561.42
Debt Equity Ratio 1.15 2.36 -1.21

Earnings Per Share and Key Ratios

The company reported negative earnings per share for both basic and diluted calculations. For FY26, the loss per share stood at ₹37.79 compared to ₹68.71 in the previous year, showing improvement despite continued losses.

Key Financial Ratios:

  • Debt Service Coverage Ratio: (0.01) for FY26 vs (1.15) for FY25
  • Interest Service Coverage Ratio: (0.04) for FY26 vs (1.48) for FY25
  • Capital Redemption Reserve: ₹0.30 lakhs (unchanged)

Regulatory Compliance

The financial results disclosure was made pursuant to Regulation 30 read with Schedule III and Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company secretary Tejashree Pradhan signed the compliance documents on April 28, 2026, ensuring proper regulatory adherence for the BSE-listed company with scrip code 533138.

Historical Stock Returns for Astec Lifesciences

1 Day5 Days1 Month6 Months1 Year5 Years
-0.81%-6.20%+19.82%+3.45%+1.00%-39.94%

What strategic initiatives will Astec LifeSciences implement to achieve profitability given the continued losses despite revenue growth?

How will the significant increase in securities premium and equity capital be utilized to drive future business expansion?

What impact will the improved debt-equity ratio have on the company's ability to secure additional financing for growth projects?

More News on Astec Lifesciences

1 Year Returns:+1.00%